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ABSTRACT
Postanesthetic shivering (POS) is a common complication following spinal anesthesia. Several
drugs have been used to prevent POS, including ondansetron and pethidine. This study was
conducted to compare the efficacy of ondansetron 8 mg with pethidine 0.4 mg/kg BW for
prevention of shivering in pregnant patients undergoing a cesarean section with spinal anesthesia.
This is a double blind controlled trial involving 96 pregnant patients between the age 18-40
years with ASA physical status I-II, gestational age of 37-42 weeks, body weight of 40-70kg or
Body Mass Index (BMI) <30, body height >145 cm who underwent a cesarean section with
spinal anesthesia in Dr. Sardjito General Hospital, Yogyakarta and affiliated hospital. Exclusion
criteria included patients or families who refused to participate in the study, having a history of
allergy to bupivacaine, ondansetron, and pethidin, patients with a fetus known to have congenital
abnormalities earlier, body temperature early > 38 ºC or <36 ºC, pregnancy with complications
(PEB, eclampsia, HELLP syndrome), and pregnant patients with heart disease (severe hypertension,
heart trouble, abnormal heart valves). The patients were randomized into two groups i.e. 48
patients of group ondansentron receiving intravenous ondansetron 8 mg and 48 patients of
group pethidine receiving intravenous pethidine 0.4 mg/kg BW. The patients were observed for
occurence and severity of POS, postoperative nausea and vomiting. The results showed that
two patients (4.2%) on the ondansetron group and six patients (12.5%) on the pethidine group
experienced of POS. Moreover, the efficacy of ondansetron in the prevention of POS (95.8%)
was higher than pethidine (87.5%). However, there were not significantly different (p>0.05).
The incidence of nausea on the ondansetron group (4.2%) was lower than the pethidine group
(16.7%) (p<0.05). However, no significant difference in the incidences of vomiting was observed
between the ondansetron (0%) dan the pethidine (4.2%) groups (p>0.05). In conclusion, the
efficacy of ondansetron 8 mg is comparable to pethidine 0.4 mg/kgBW for prevention of shivering
in pregnant patients after spinal anesthesia.
ABSTRAK
Postenesthetic shivering (POS) adalah komplikasi yang umum terjadi setelah tindakan anestesi
spinal. Beberapa obat telah digunakan untuk mencegah POS termasuk ondansetron dan petidin.
Penelitian ini dilakukan untuk membandingkan efektivitas ondanstron 8 mg dengan petidin 0,4
mg/kg BB untuk mencegah POS pada pasien hamil yang menjalani operasi sesar dengan anestesi
spinal. Penelitian ini merupakan uji klinik tersamar ganda melibatkan 96 pasien berumur 18-40
tahun dengan status fisik ASA I dan II, umur kehamilan 37-42 minggu, berat badan 40-70 kg
(BMI <30), tinggi badan >145 cm yang menjalani bedah sesar dengan anestesi spinal di RSUP
Dr. Sardjito, Yogyakarta dan rumah sakit afiliasi. Kriteria pengeluaran adalah pasien atau keluarga
menolak terlibat penelitian, mempunyai riwayat alergi bupivakain, ondansetron, dan petidin,
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pasien dengan janin diketahui mempunyai kelainan kongenital sebelumnya, temperatur awal
>38 oC atau <36 oC, kehamilan dengan komplikasi (PEB, eklamsia dan simdrom HELLP), dan
pasien hamil dengan kelainan jantung (hipertensi berat, gangguan jantung, kelainan denyut
jantung). Pasien diacak menjadi dua kelompok yaitu 48 psien kelompok ondansetron yang
menerima ondanstron 8 mg intravena dan 48 pasien kelompok petidin 0.4 mg/kg BB intravena.
Pengamatan dilakukan terhadap kejadian dan keparahan POS, mual dan mutah pasca operasi.
Hasil penelitian menunjukkan dua pasien (4,2%) pada kelompok ondansetron dan enam (12,5%)
pada kelompok petidin mengalami POS. Efikasi ondansetron dalam mencegah POS (95.8%)
lebih tinggi dari petidin (87,5%). Namun demikian tidak terdapat perbedaan nyata (p>0,05).
Kejadian mual pada kelompok ondansetron (4,2%) lebih rendah dari pada kelompok petidin
(16.7%) (p<0,05). Namun demikian kejadian mutah tidak berbeda nyata pada kelompok
ondansetron (0%) dan petidin (4,2%) (p>0,05). Dapat disimpulkan, efikasi ondansetron 8 mg
sebanding dengan petidin 0,4 mg/kg BB untuk mencegah shivering pada psien hamil setelah
tindakan anestesi spinal.
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INTRODUCTION
Postanesthetic shivering (POS) is an
involuntary movement that may affect one or
several muscle groups. Postanesthetic shivering
is a common complication following general
anesthesia and also occurs intraoperatively
during moderate and deep sedation.1-3 The
incidence of POS is reported between 5 up to
60% of patients recovering from general
anesthesia and up to 30% of patients receiving
epidural anesthesia.4,5 Age, gender, type of
anesthesia, amount and temperature of
intravenous fluids, duration of surgery and
temperature of operating room seem to be
determinant factors of POS.1-5
The body thermoregulatory system
coordinates defense against temperature changes
to maintain body temperature within a normal
range by optimizing normal body function. The
central thermoregulatory control is the
hypothalamus. Spinal anesthesia induces
thermoregulatory impairment and leads to
hypothermia. The hypothermia results from
redistribution of body heat to periphery.
Normally, heat loss is regulated by cutaneous
vasodilation or vasoconstriction, sweating, and
shivering. Shivering is an important complicat-
ion of hypothermia. Shivering is a last defense
that is activated only when behavioral
compensations and maximal arterio venous
shunt vasoconstriction are insufficient to
maintain body temperature.1-3 It is an involun-
tary, oscillatory muscular activity that augment
metabolic heat production up to 600% above
basal level.6,7
The first clinical consequence of POS is
the discomfort for the patients. Moreover, it is
associated with number of deleterious of
sequelae. These include increased oxygen
consumption and carbon dioxide production,
cathecolamine release, a significant increased
metabolic acidosis, increased cardiac output,
tachycardia and hypertension, raised intraocular
and intracranial pressures, increased risk of
incidental trauma, and disrupts medical
devices.6-8 Postanesthetic shivering may also
decrease mix venous oxygen saturation as well
as interfering with electrocardiogram and pulse
oxymetri monitoring.9,10
A wide range of drugs have been used to
prevent POS, including pethidine and other
opioids suc as fentanyl, sulfentanil, and mepe-
ridine,5,6 tramadol,4,5 ketamine,11 clonidine,12
and benzoxazocine.13 Pethidine is remarkably
effective to treat POS. Pethidine 25-50 mg doses
is sufficient when given intravenously for
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prevention and treatment of shivering in the
majority of adults. Pethidine has long been used
as standard therapy to prevent and treat shivering
postanesthetic action. 5-7
Postanesthetic shivering is accosiated with
stimulation of seretonin or 5-hydroxytryptamine
(5-HT) receptor in the brain and spinal cord.
The 5-HT receptor plays an important role in
control of the heat production and loss of body
heat.14 Antagonist of 5-HT3 such as ondanstron
and granisetron is reported to have effect against
POS.14-16 Moreover, ondansetron has been
shown to be effective in the prevention of post-
operative nausea and vomiting (PONV).17 An
agent to reduce both POS and PONV will be
very benefit.18 This study was conducted to
evaluate the efficacy of intravenous bolus of
ondansetron 8 mg in comparison to intravenous
bolus of pethidine 0.4 mg/kg BW for prevention
of shivering in pregnant patients undergoing a
cesarean section with spinal anesthesia.
MATERIALS AND METHODS
Subjects
This was a randomized double-blind
clinical trial conducted after approval from the
Medical and Health Research Ethic Committee,
Faculty of Medicine, Universitas Gadjah Mada,
Yogyakarta and obtaining a written informed
consent. Atotal of 96 pregnant women patients
between the age 18-40 years withASAphysical
status I-II, gestational age of 37-42 weeks, body
weight of 40-70kg or Body Mass Index (BMI)
<30, body height >145 cm who underwent a
cesarean section with spinal anesthesia
techniques in Dr. Sardjito General Hospital,
Yogyakarta and affiliated hospital i.e. Dr.
Soeradji General Hospital, Klaten, Central Java,
Banyumas General Hospital, Central Java and
Panembahan Senopati District Hospital, Bantul,
Yogyakarta for period of February to June 2011.
Exclusion criteria included patients or families
who refused to participate in the study, having
a history of allergy to bupivacaine, ondansetron,
and pethidin, patients with a fetus known to have
congenital abnormalities earlier, body
temperature early > 38 ºC or <36 ºC, pregnancy
with complications (PEB, eclampsia, HELLP
syndrome), and pregnant patients with heart
disease (severe hypertension, heart trouble,
abnormal heart valves). Drop out criteria
included patients experienced total spinal,
sensory and motor block (T4-T8) not happened
15 minutes after anesthesia, spinal anesthesia
considered fail, withdrew from the research and
bleeding complications (uterine atony). The
patients were randomly allocated to one of two
groups i.e. 48 patients of group ondansentron
receiving 8 mg ondansetron as an intravenous
bolus injection and 48 patients of group
pethidine receiving pethidine 0.4 mg/kg BW as
an intravenous bolus injection.
Protocol of study
Preoperative visit and checkup were
performed before surgery and characteristics of
patients were taken. A detail operating
procedure conducting was explained to all
patients. The patients who were willing to be
involved in the study would signed an inform
consent. The patient was placed in the surgery
preparation room and an intravenous line was
installed using abbocath 18G on the dorsum
manus vein of the hand and ringer lactate
solution was infused at dosage of 2 cc/kg BW/
hour for 30 minutes. Operating room temperature
was maintaines at 20-26 oC. After shifting the
patients to operation table, preoperative vital
parameters like electrocardiogram (ECG), pulse
rate (PR), respiratory rate (RR), non invasive
blood pressure (NIBP), mean arterial pressure
(MAP), heart rate (HR) and SpO2 rate were
monitored and recorded prior to the anesthetic
procedure. Ten minutes before spinal anesthesia,
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8 mg ondansetron or pethidine 0.4 mg/kg BW
was given as an intravenous bolus injection. The
patients were placed in sitting or lateral
dicubitus position and the spinal anesthesia was
performed at the L3-4 lumbar region puncturing
with a 25 G needle under sterile technique.
Local anesthesia was conducted using 12.5 mg
of 0.5% hyperbaric bupivacaine. The patients
were then placed in the modified supine position
with a pillow. The level of sensory blockade
was evaluated using pinprick method at the
second minute after spinal induction and
continued in five-minute interval for 15 minutes.
Standards for patient hemodynamic monitoring
during anesthesia i.e. MAP, PR and RR was
performed in five-minute interval for the first
15 minutes and then in fifteen-minute interval
from the time just after the anesthesia started to
the end of the operation. Oxygen
supplementation was given using nasal
cannulae. In the case of hypotention or blood
pressure dropped >20%, 5-20 mg of ephedrine
was given as an intravenous bolus injection. The
patients were observed for occurence and
severity of POS, postoperative nausea and
vomiting, axilla and tympanic membrane
temperature in fifteen-minute interval from the
time just after anesthesia strated to the end of
the operation and then thirty-minute interval
from the end of the operation to the patients were
placed in the recovery room. An intravenous
bolus injection of pethidine 25 mg was given to
patients with shivering. Moreover, intravenous
of analgesic ketorolac 30 mg was given before
the end of the operation. The severity of POS
was measured as conducted by Crossley and
Mahajan19 with the criteria presented in TABLE
1. Data were recorded on the predesigned data
collection form.
Statistical analysis
Data were tabulated and presented as mean
± standard deviation (SD) or percent. Data of
incidence and severity of shivering and the side
effects of drugs of ondansetron and pethidine
groups were analyzed statistically using Chi
square test. Data of age, weight, hemodynamic
chages, axilla and tympanic membarane
temperatures, operation room temperature were
analyzed statistically using independent t-test.
A p value <0.05 was considerd statistically
significant. All statistic analysis was performed
using SPSS version 15 computer program.
RESULTS
Forty eigth patients were involved in each
group of this study. The characteristics of
patients of both groups are presented in TABLE
2. No significant difference was observed in
terms of age, weight, height, BMI, systolic and
diastolic blood pressure, MAP, HR, RR, axilla
and tympani temperatures, and room
temperature between the groups (p>0.05). It was
indicated that the patients characteristics of both
groups were comparable.
TABLE 1. Grade of shivering
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TABLE 2. Characteristics of subjects (mean ± SD or percent) of ondansetron and
pethidine groups
The incidences of POS at different time
intervals on the group of ondansetron and the
group of pethidine are presented in TABLE 3,
while the severity of POS are presented in
TBALE 4. No significant difference in the
incidences and the severity of POS between
the two gropus was also also observed
(p>0.05).
TABLE 3. The incidence of POS at different time intervals
on ondansetron and pethidine groups
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TABLE 4. The severity of POS at different time intervals on
ondansetron and pethidine groups
The patients who experienced of POS on
the group of ondansetron and pethidine are
presented in TABLE 5. Two patients (4.2%) on
the group of ondansetron and 6 patients (12.5%)
experienced of POS. Moreover, the effectivenss
of ondansetron in the prevention of POS after
spinal anesthesia (95.8%) was higher than
pethidine (87.5%). However, ther were not
significantly different (p>0.05).
133
Ferianto et al., The efficacy of ondansetron in comparison with pethidine for prevention of shivering
in pregnant patients undergoing a cesarean section with spinal anesthesia
TABLE 5. The patients who experienced of POS on
ondansetron and pethidine groups
The axilla and tympani temperatures after
spinal anesthesia at different time intervals on
the group of ondansetron and the group of
pethidine are presented in TABLE 6. The axilla
temperature of patients on the group of
ondansetron in the 15; 30; 45; 60 dan 75 minutes
after spinal anesthesia was normally
significantly higher than the group of pethidine
(p<0.05), while in the 90 and 120 minute was
not significantly different (p>0.05). Further-
more, the tympani termperature of patients on
the group of ondansetron at different time
intervals of observation was normally
significantly higher than the group of pethidine
(p<0.05), except in the 120 minute. No
significant difference of the tympani temperature
was observed in the 120 minute after spinal
anesthesia on the both groups (p>0.05).
TABLE 6. The body temperature at different time intervals on ondansetron
and pethidine groups
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The block heights after spinal anesthesia at
different time intervals on the group of
ondansetron and the group of pethidine are
presented in TABLE 7. The block heigths in the
minute 2 and 5 on the group of ondansetron was
not significantly different compared to the group
of pethidine (p>0.05). However, the block
height on the group of ondansetron in the minute
10 and 15 was significantly different compared
to the group of pethidine (p<0.05).
TABLE 7. The block heights after spinal anesthesia at different time
intervals on on ondansetron and pethidine groups
The incidence of side effects of drugs i.e.
nausea and vomiting after spinal anesthesia on
ondanstron and pethidine groups are presented
in TABLE 8. The incidence of nausea on the
ondansetron group (4.2%) was lower than the
pethidine group (16.7%) (p<0.05). No
significant difference in the incidences vomiting
was observed between the ondansetron (0%)
dan the pethidine groups (4.2%) (p>0.05).
TABLE 8. The incidence of nausea and vomiting on ondansetron and
pethidine groups
* p< 0.05 = statistically significant difference
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The incidence of shivering on patients who
had history of misoprostol administration on the
ondanstron and the pethidine groups is presented
in TABLE 9. No significant difference in the
incidence of shivering on patients who had
history of misoprostol administration was
observed between both groups (p>0.05).Among
8 patients who experienced shivering, just 1
(12.5%) patient having history of misoprostol
administration, while 7 (87.5%) patients not
having of history of mistoprostol administration,
whereas from 88 patients who not experienced
shivering, there just 9 (10.2%) patients having
history of mistoprostol administration, whereas
79 (89.8%) not having of histroy of mistoprostol
administration.
TABLE 9. The incidence of shivering on patients who had history of
misoprostol administration on ondansetron and the pethidine
groups
The length of operation, fluid administrat-
ion, and bleeding during spinal anesthesis on
the ondansetron and the phetidine groups are
presented in TABLE 10. No significant different
in the length of operation, fluid administration,
and bleeding were observed between the both
groups (p>0.05).
TABLE 10. Length of operation, fluid administration, and bleeding (mean ± SD) during spinal
anesthesis on the ondansetron and the phetidine groups.
DISCUSSION
Ondansetron is a 5-HT3 antagonist that it is
indicated to prevent nausea and vomiting.17 In
addition, ondansetron is useful for prevention
of shivering in patients undergoing spinal
anesthesia, regional anesthesia and pain
medicine.16 In this study we reported the efficacy
of intravenous bolus of ondansetron 8 mg in
comparison to intravenous bolus of pethidine
0.4 mg/kg BW for prevention of POS in pregnant
patients undergoing a cesarean section with spinal
anesthesia. The incidence of POS was observed
in 15 minutes time intervals during 120 minutes.
The results showed that the incidence of POS
betweengroupsofondan-setronandpethidinewas
not significantly different (p> 0.05) (TABLE 3).
Moreover, the severity of POS in both groups
were laso not significantly different (p>0.05)
(TABLE 4). The severity of POS varied from
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degree 1 to degree 4. Pethidine 25 mg
intravenouly was given to patients who suffering
from POS at degree 3 and 4.
Normally, the incidence of POS was
observed at 45, 60 and 75 minutes time
intervals, although at 15, 90 and 120 mintues
time interval, the incidence of POS was also
observed (TABLE 4). It is reported that the
incidence of POS occurs noramlly at 0.5 to 1
hour after patients undergoing spinal anesthesia.
During temperature measurement, the axillary
temperature decreases significantly in the minute
15 until the minute 75, while the tympanic
temperature decreases significanlty in the minute
15 untul the minute 90. The axillary and
tympanic temperatures are generally tounght to
be the most accurate for checking a body
temperature. The decrease of axillary and
tympanic temperatures reflecting the decrease
of the body temperature or hypotermia leads to
the POS as a compensation of the body to
increase heat production. Kelsaka16 and Powel
and Buggy20 reported that patients who
underwent spinal or epidural anesthesia can not
maintain the central temperature due to impaired
peripheral vasoconstriction. In addition, the
patients who underwent spinal anesthesia
produce relatively little heat due to only small
part of the muscles that contract i.e. just part of
the blocked chepalad.
Among 48 patients who underwent the
cesarean section with spinal anesthesia in the
ondansetron group, only two patients (4.2%)
suffer POS indicating that its effectiveness in
reducing of POS is 95.8%. While in pethidine
group, among 48 patients who underwent the
cesarean section, six patients (12.5%) suffer
POS indicating that its effectiveness is 87.5%.
The effectiveness of ondansetron in reducing
of POS has been reported by some authors
varying from 84 to 92% 16,20,21 while the
effectiveness of pethidine varied from 84 to
90%.14,21,22
The side effects of drugs including nausea
and vomiting were observed in this study. The
incidence of nausea on ondansetron group
(4.2%) was significantly lower than pethidine
group (16.7%) (p<0.05). Moreover, the
incidence of vomiting was just observed on
pethidine group (4.2%) although it was not
significantly difference compare to ondansetron
group (p>0.05). This study was in accordance
with the previous studies indicating that the side
effects of nausea and vomiting were lower on
the ondansetron group compare to pethidine
group.16 The higher incidence of nausea and
vomiting on pethidine group was caused by its
stimuli effect directly on the vomiting center in
the chemoreceptor trigger zone. In contrast,
ondansetron is an antagonist of 5-HT3 that it is
indicated to prevent nausea and vomiting.17 The
results of this study support the previous study
indicating that ondansetron can reduce both POS
and PONV.17,18
The disadvantage of ondansetron to prevent
POS has been indicated. Ondansetron is related
to the incidence of heart rhythm disorders such
as arrythmias. The incidence of arrhytmias due
to ondansetron has been reported in the previous
studies although it is relatively rare. Moreover,
ondansetron has a wide dosage range with the
maximum doses of 100 mg/day therefore
ondansetrone is relatively safe. The side effect
of arrhytmias due to ondansetron is normally
suffered patients who a history of QT
prolongation or QT syndrome with electrolyte
disturbances and severe hepatic function.
Therefore, Food and Drug Administration
(FDA) USA is not recommended ondansetron
for these patients.16,23,24
The history of misoprostol administration
of patients did not influence the incidence of
POS (p>0.05). Among eight patients who
experienced POS, only one patients who had a
hostory of misoprostol administration.
Misoprostol is reported to have side effect of
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shivering that it is accociated with dose and
time administration. The side effect of shivering
appears after 2-6 hours misoprostol
administration in high dose.16,25,26
CONCLUSION
In conclusion, the efficacy of ondansetron
8 mg intravenous bolus is comparable to
pethidine 0.4 mg/kgBW intravenous bolus for
prevention of shivering in pregnant patients after
spinal anesthesia. In addition, the incidence of
nausea after ondansetron administration is
significantly lower than after pethidine
administration.
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